RVMD Q1 2025 Earnings
Reported May 7, 2025 at 4:05 PM ET · SEC Source
Q1 25 EPS
$-1.13
MISS 7.02%
Est. $-1.06
Q1 25 Revenue
N/A
Est. $0
vs S&P Since Q1 25
+230.1%
BEATING MARKET
RVMD +257.6% vs S&P +27.5%
Market Reaction
Did RVMD Beat Earnings? Q1 2025 Results
Revolution Medicines posted a deeper-than-expected loss in Q1 2025, with earnings per share of -$1.13 missing the consensus estimate of -$1.06 by 7.02%, as the pre-revenue oncology company accelerated spending across its RAS(ON) inhibitor pipeline. T… Read more Revolution Medicines posted a deeper-than-expected loss in Q1 2025, with earnings per share of -$1.13 missing the consensus estimate of -$1.06 by 7.02%, as the pre-revenue oncology company accelerated spending across its RAS(ON) inhibitor pipeline. The primary driver was a near-doubling of R&D expenses to $205.75 million, up from $118.02 million a year ago, pushing the net loss to $213.42 million compared to $116.00 million in Q1 2024. The company generated no revenue during the quarter, consistent with its clinical-stage status. Despite the widening losses, management reiterated full-year 2025 GAAP net loss guidance of $840 million to $900 million and pointed to $2.10 billion in cash as sufficient to fund operations into the second half of 2027. The spending acceleration coincided with meaningful pipeline progress, including a 61% objective response rate for zoldonrasib in KRAS G12D NSCLC and an 86% ORR for daraxonrasib combined with pembrolizumab in first-line NSCLC, underscoring the breadth of assets advancing toward potential pivotal trials.
Key Takeaways
- • Increased R&D spending driven by clinical trial expenses and manufacturing for daraxonrasib, zoldonrasib, and elironrasib
- • Headcount growth driving higher personnel-related expenses and stock-based compensation across R&D and G&A
- • Increased commercial preparation activities ahead of potential product launches
RVMD YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
“We are executing well in our ongoing registrational studies of daraxonrasib in patients with previously treated PDAC and NSCLC, and continuing preparations to start the earlier-line PDAC trials this year. Today we've shared important data from all three of our clinical-stage investigational RAS(ON) inhibitors that reinforce exciting opportunities in NSCLC.”
— Mark A. Goldsmith, Q1 2025 Earnings Press Release
RVMD Earnings Trends
RVMD vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
RVMD EPS Trend
Earnings per share: estimate vs actual
RVMD Revenue Trend
Quarterly revenue: estimate vs actual
RVMD Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 MISS FY | $-1.58 | $-1.86 | -17.72% | — | — |
| FY Full Year | $-5.53 | $-5.95 | -7.53% | — | — |
| Q3 25 MISS | $-1.41 | $-1.61 | -14.25% | — | — |
| Q2 25 MISS | $-1.12 | $-1.31 | -16.75% | — | — |
| Q1 25 MISS | $-1.06 | $-1.13 | -7.02% | — | — |